Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 86/100

Experience significant relief from inflammatory or autoimmune symptoms by physically clearing harmful proteins from your blood, a process that may also remove age-accumulated factors to promote long-term systemic rejuvenation.

Knowledge Graph:Vector: Cancer DefenseIntercellular Signaling
Head-to-Head CompareAudit in Stack
PhysicalCancer DefenseSilver Tier85–941stin Intercellular Signaling of 743rdin Pain of 8Emerging Confidence⚖️ Scientific Consensus: Stable

Plasmapheresis / Therapeutic Plasma Exchange

Experience significant relief from inflammatory or autoimmune symptoms by physically clearing harmful proteins from your blood, a process that may also remove age-accumulated factors to promote long-term systemic rejuvenation.

86/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Experience significant relief from inflammatory or autoimmune symptoms by physically clearing harmful proteins from your blood, a process that may also remove age-accumulated factors to promote long-term systemic rejuvenation.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:32729906

Plasma Exchange with Albumin Replacement in Patients with Mild-to-Moderate Alzheimer Disease: The AMBAR Multicenter Randomized Controlled Trial

OPEN LABEL RCT • Sample: N = 347

“ADAS-Cog and ADCS-ADL Neuropsychological Scores: -61%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Therapeutic Plasma Exchange (TPE / Plasmapheresis).

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Therapeutic Plasma Exchange (TPE / Plasmapheresis).

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

No direct primary biochemical modulation of metabolic health; pathway is neutral for Therapeutic Plasma Exchange (TPE / Plasmapheresis).

Cancer Defense & Autophagy

Foundational Target (65-100)
94/ 100

Centrifugal apheresis separates and discards 2.5-3.0 liters of patient plasma containing accumulated pro-aging cytokines, autoantibodies, and oxidized albumin, replacing it with fresh 5% sterile human albumin solution; unmasks youth-associated systemic tissue regeneration (the Conboy heterochronic exchange paradigm).

Circulating SASP CytokinesAlbumin Oxidation RatioEpigenetic DNAm Age DeltaTGF-beta1
Rejuvenation of three germ layers by blood exchange in humans and micePMID: 32488349

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Therapeutic Plasma Exchange (TPE / Plasmapheresis).

Systemic Inflammation Suppression

Foundational Target (65-100)
94/ 100

Centrifugal apheresis separates and discards 2.5-3.0 liters of patient plasma containing accumulated pro-aging cytokines, autoantibodies, and oxidized albumin, replacing it with fresh 5% sterile human albumin solution; unmasks youth-associated systemic tissue regeneration (the Conboy heterochronic exchange paradigm).

Circulating SASP CytokinesAlbumin Oxidation RatioEpigenetic DNAm Age DeltaTGF-beta1
Rejuvenation of three germ layers by blood exchange in humans and micePMID: 32488349

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Therapeutic Plasma Exchange (TPE / Plasmapheresis).

Cellular Longevity & Epigenetics

Foundational Target (65-100)
94/ 100

Centrifugal apheresis separates and discards 2.5-3.0 liters of patient plasma containing accumulated pro-aging cytokines, autoantibodies, and oxidized albumin, replacing it with fresh 5% sterile human albumin solution; unmasks youth-associated systemic tissue regeneration (the Conboy heterochronic exchange paradigm).

Circulating SASP CytokinesAlbumin Oxidation RatioEpigenetic DNAm Age DeltaTGF-beta1
Rejuvenation of three germ layers by blood exchange in humans and micePMID: 32488349
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Circulating Pro-Aging Factor Purging & Stem Cell De-Inhibition
Secondary Clinical Endpoints:
Hepatic and Cerebral Fibrosis AttenuationCerebrospinal Fluid Biomarker RejuvenationCognitive Decline Deceleration in Alzheimer Cohorts (AMBAR Trial)
LEVL Recommended Tracking Metrics:
cellular healthepigenetic agelongevity

Systemic Rejuvenation

96/99
Very High EffectGrade A (AMBAR Phase 2b/3 Multicenter RCT & Conboy Studies)Periodic clinical hospital/clinic procedure
AMBAR Trial: Plasma Exchange in Mild-to-Moderate Alzheimer DiseasePMID: 32729906

Clinical Endpoint: Stabilized cognitive and functional decline by 61% over 14 months in mild-to-moderate Alzheimer cohorts in the landmark AMBAR trial.

systemic_rejuvenation

Energy

daily wellbeing
91/99
Very High EffectGrade A (Human Clinical RCT)2-4 weeks
Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravisPMID: 12494432

Clinical Endpoint: A randomized trial in myasthenia gravis patients showed plasma exchange was significantly effective in improving muscle strength and reducing functional disability during acute exacerbations, directly translating to increased energy.

energy

Pain

daily wellbeing
85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
Plasma exchange for Guillain-Barré syndromePMID: 22786491

Clinical Endpoint: This Cochrane review of randomized trials found that plasma exchange significantly hastens recovery from Guillain-Barré syndrome, a condition often characterized by severe neuropathic pain and weakness.

pain

Brain Fog

daily wellbeing
78/99
High EffectGrade B (Clinical Evidence)3-8 weeks
Therapeutic Plasma Exchange for the Treatment of Age-Associated Chronic Inflammatory States: A Proof of ConceptPMID: 28211211

Clinical Endpoint: This pilot study demonstrated that TPE significantly reduced levels of key pro-inflammatory cytokines (e.g., IL-6, TNF-α, hs-CRP) known to be associated with aging and cognitive symptoms like brain fog.

brain_fog
Explainable Longevity Score Decomposition

Score Breakdown: 86 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength71/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude97/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility82/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=347 pooled participants) across 71/100 evidence strength and 97/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
$30–$100 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Plasmapheresis / Therapeutic Plasma Exchange Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
347
Avg RoB
1.3 / 5
Human Clinical (n=347)Open-Label RCTGRADE: Very High
Risk of Bias: 1.3

Plasma Exchange with Albumin Replacement in Patients with Mild-to-Moderate Alzheimer Disease: The AMBAR Multicenter Randomized Controlled Trial

Boada M, et al.•Alzheimer & Dementia•2020•N = 347•60 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
ADAS-Cog and ADCS-ADL Neuropsychological Scores-61%
-61%p < 0.05
Clinical Takeaway:Therapeutic plasma exchange with albumin replacement resulted in 61% less progression of disease in moderate Alzheimer patients compared to placebo sham apheresis.
Independent Academic Research
PubMed: 32729906DOI
Chronological Evolution of Evidence

Plasmapheresis / Therapeutic Plasma Exchange Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Plasmapheresis / Therapeutic Plasma Exchange Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)